5-Amino-1MQ Pricing: April 2026

5-Amino-1MQ (5-Amino-1-methylquinolinium) is a small molecule sold for fat loss and longevity. It is often grouped with peptides, but it is a methylquinolinium analog rather than a peptide. That distinction shapes who can sell it and how.

How it works: 5-Amino-1MQ blocks NNMT (nicotinamide N-methyltransferase), an enzyme in fat tissue that consumes methyl groups. Blocking it preserves the cell's NAD+ and SAM pools, which in rodent studies raised SIRT1 sirtuin activity, improved mitochondrial function, increased fat oxidation, and reduced white fat tissue.

Clinical evidence: No human clinical trials have been published, so all dosing is extrapolated from rodent data (Kannt and colleagues, 2018, Nat Chem Biol).

Standard protocol: 50–150 mg by mouth once daily, in the morning or before a workout. A typical ramp starts at 50 mg for 1–2 weeks and then settles at 100 mg daily, the most common maintenance dose. Some go to 150 mg, the upper end, though results reportedly plateau beyond that. Cycles run 8–12 weeks on, then 4–8 weeks off.

Forms: Oral capsules dominate, with 50 mg the standard strength and 60 per bottle the usual count. Freeze-dried (lyophilized) powder is also sold for research, but the buyer has to fill their own capsules.

Regulatory status (April 2026): Not FDA-approved. Because it is a small molecule and not a peptide, it was left out of the February 2026 peptide reclassification, and it is not on the FDA's 503A bulk substances list. A 503A pharmacy makes patient-specific compounded drugs from a doctor's prescription, while a 503B facility compounds in bulk for clinics. Neither dispenses 5-Amino-1MQ through standard channels. Mainstream telehealth platforms (Maximus, Hone Health, AgelessRx, Henry Meds, Strut, BeyondMD) do not publicly prescribe it either. Access is limited to specialty clinics and research vendors, who sell it "for research use only," meaning no prescription and no legal human use. The gap looks a lot like the one for MK-677.

Common stacks: NAD+ injections, NMN, or NR to preserve the NAD+ pool; MOTS-c for mitochondrial and metabolic support; and GLP-1 drugs (semaglutide, tirzepatide) for visceral fat loss. Insurance does not cover 5-Amino-1MQ.